This study found that FGNs could treat acute myeloid leukemia subtype 2 (AML-M2) by silencing five essential oncogenes (BAG1, MDM2, Bcl-2, BIRC5, and XIAP) in AML-M2. Here, BCL2 is linked to acute myeloid leukemia.